VERTEX PHARMACEUTICALS INC / MA Investment Income, Interest
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Investment Income, Interest of $497.00 thousand for the 3-month period ending 2012-12-31, per its 10-K filed 2013-03-01.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2013-03-01
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for the quarter ending 2012-12-31 was $497.00K, a 152.28% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for the quarter ending 2012-09-30 was $519.00K, a 574.03% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for the quarter ending 2012-06-30 was $560.00K, a 177.23% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for the quarter ending 2012-03-31 was $364.00K, a 74.04% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for fiscal 2012 was $1.94M, a 3.30% increase from fiscal 2011.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for fiscal 2011 was $1.88M, a 3.94% decline from fiscal 2010.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for fiscal 2010 was $1.96M, a 60.98% decline from fiscal 2009.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest for fiscal 2009 was $5.01M, a 69.32% decline from fiscal 2008.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2012-12-31 | $497.00K 10-K · filed 2013-03-01 | $1.02M derived: sum of 2 quarters · filed 2013-03-01 | $1.58M derived: sum of 3 quarters · filed 2013-03-01 | $1.94M 10-K · filed 2013-03-01 |
| 2012-09-30 | $519.00K 10-K · filed 2013-03-01 | $1.08M derived: sum of 2 quarters · filed 2013-03-01 | $1.44M 10-Q · filed 2012-11-06 | $1.64M derived: sum of 4 quarters · filed 2013-03-01 |
| 2012-06-30 | $560.00K 10-K · filed 2013-03-01 | $924.00K 10-Q · filed 2012-08-08 | $1.12M derived: sum of 3 quarters · filed 2013-03-01 | $1.20M derived: sum of 4 quarters · filed 2013-03-01 |
| 2012-03-31 | $364.00K 10-K · filed 2013-03-01 | $561.00K derived: sum of 2 quarters · filed 2013-03-01 | $638.00K derived: sum of 3 quarters · filed 2013-03-01 | $840.00K derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-12-31 | $197.00K 10-K · filed 2013-03-01 | $274.00K derived: sum of 2 quarters · filed 2013-03-01 | $476.00K derived: sum of 3 quarters · filed 2013-03-01 | $1.88M 10-K · filed 2013-03-01 |
| 2011-09-30 | $77.00K 10-K · filed 2013-03-01 | $279.00K derived: sum of 2 quarters · filed 2013-03-01 | $1.68M 10-Q · filed 2012-11-06 | $2.20M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $202.00K 10-K · filed 2013-03-01 | $1.60M 10-Q · filed 2012-08-08 | $2.13M derived: sum of 3 quarters · filed 2013-03-01 | $2.62M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $1.40M 10-K · filed 2013-03-01 | $1.93M derived: sum of 2 quarters · filed 2013-03-01 | $2.42M derived: sum of 3 quarters · filed 2013-03-01 | $2.90M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $523.00K 10-K · filed 2012-02-22 | $1.02M derived: sum of 2 quarters · filed 2012-02-22 | $1.50M derived: sum of 3 quarters · filed 2012-02-22 | $1.96M 10-K · filed 2013-03-01 |
| 2010-09-30 | $493.00K 10-K · filed 2012-02-22 | $977.00K derived: sum of 2 quarters · filed 2012-02-22 | $1.43M 10-Q · filed 2011-11-03 | $1.76M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $484.00K 10-K · filed 2012-02-22 | $939.00K 10-Q · filed 2011-08-09 | $1.27M derived: sum of 3 quarters · filed 2012-02-22 | $1.86M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | $455.00K 10-K · filed 2012-02-22 | $782.00K derived: sum of 2 quarters · filed 2012-02-22 | $1.38M derived: sum of 3 quarters · filed 2012-02-22 | $2.87M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | $327.00K 10-K · filed 2011-02-17 | $922.00K derived: sum of 2 quarters · filed 2011-02-17 | $2.41M derived: sum of 3 quarters · filed 2011-02-17 | $5.01M 10-K · filed 2012-02-22 |
| 2009-09-30 | $595.00K 10-K · filed 2011-02-17 | $2.08M derived: sum of 2 quarters · filed 2011-02-17 | $4.68M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $1.49M 10-K · filed 2011-02-17 | $4.09M 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | $2.60M 10-K · filed 2011-02-17 | |||
| 2008-12-31 | $16.33M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |